Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.54

-3.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	9/17/2004 2:42:50 PM
From: Harold Engstrom	Read Replies (2) of 52153

Indevus has popped up a bit over the past week as initial script data for Sanctura is presumably known to some. Jim McCamant was predicting $250MM-$350MM annual Sanctura sales within 2 years (arrived at through some company guidance at a conference I believe.) There is a bit more to the pipeline after the Fen Fen disaster (co indemnified by Wyeth.) Can we give that pipeline more credibility now that Sanctura is being prescribed sucessfully?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next